Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

tiated in 2006 and 2007. We expect research and development expenses to trend down in the fourth quarter and into 2009 as we collect clinical data and evaluate each program to determine future clinical direction. At the end of the quarter we reported $27.9 million in cash and short-term investments, which together with anticipated royalty inflows, we believe will fund planned operations for at least the next 12 months."

James S. Burns, EntreMed President and Chief Executive Officer, commented, "We are actively pursuing partners for ENMD-2076 and Panzem(R) RA while continuing our clinical oncology programs, including the Phase 1b dose-escalation study in solid tumors for ENMD-2076. The outcome of our partnering initiatives and anticipated clinical progress will guide our priorities through year-end and into 2009. While we are reducing overall expenses, our clinical trials remain on schedule. We anticipate the presentation of clinical and preclinical data for MKC-1, ENMD-2076 and ENMD-1198 over the next several quarters."

Mr. Burns will present a Company overview at the Rodman & Renshaw 10th Annual Healthcare Conference, which will serve as the Company's third quarter 2008 update. Mr. Burns' presentation is scheduled for 2:25 p.m. (ET) on Tuesday, November 11, 2008 and will be web cast. To access the live presentation, visit the Company's web site at http://www.entremed.com. An archive of the presentation will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 ... throughput research solutions for biopharmaceutical development, today announced ... - 24, 2014 at GlaxoSmithKline (GSK) in Ware, ... discussions of best practices in high throughput research ... R&D leaders gathered together to discuss the challenges ...
(Date:10/2/2014)... 02, 2014 At a time when many ... has introduced a new kind of squeeze aimed at ... the Scienceware® Squeeze Rite™ Wash Bottle , catalog no. ... within the bottle reduces the waste of reagents, solutions and ... liquids. , “Easier to squeeze when compared to standard 500ml ...
(Date:10/2/2014)... 2, 2014 SIRO Clinpharm, an ... at the prestigious Annual Conference of the Society for ... Vegas , where they were invited to speak ... like ,data analytics to support fraud detection, ,clinical data ... ,benefits of working together as virtual and integrated teams,. ...
(Date:10/1/2014)... Switzerland (PRWEB) October 01, 2014 ... the quality of the final product. However, while ... regulated, regulatory frameworks such as Good Manufacturing Practices ... the responsibility of the manufacturer to interpret these ... consistent weighing performance quality. METTLER TOLEDO experts have ...
Breaking Biology Technology:Freeslate European Summit Highlights Best Practices in High Throughput Research and Data Management 2New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2SIRO Clinpharm Showcases Biometrics Capabilities at the SCDM 2014 Annual Conference in Las Vegas 2Comply with Weighing-Related Regulations in Pharma Manufacturing 2
... Aug. 28 Medivation, Inc.,(Nasdaq: MDVN ) today ... will present at the following conferences:, -- BioCentury,s ... 9:00 a.m. Eastern Time at the Millennium Broadway Hotel ... Conference on Wednesday, September 24,at 4:30 p.m. Eastern Time ...
... Exclusion of Venous Thromboembolism-, LEXINGTON, Mass., Aug. ... US Food and Drug Administration (FDA) has,granted 510(k) ... HemosIL D-Dimer,assay to exclude venous thromboembolism (VTE) in ... embolism (PE), when used in,conjunction with a clinical ...
... (ESA) has appointed the UK,s National Physical Laboratory (NPL) ... will lead a consortium to identify the next generation ... in future space missions. , "Advances in nanotechnology are ... Research Scientist in the nanomaterials group at NPL, who ...
Cached Biology Technology:Medivation Announces Participation in Upcoming Conferences 2Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay 2
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... Prenatal exposure to tetrachloroethylene (PCE) in drinking water ... abruption, according to a new study led by ... , The study, published in the journal ... 1,019 unexposed pregnancies among 1,766 women in Cape ... late 1960s to the early 1980s by the ...
(Date:9/30/2014)... runoff in Hawaii is causing tumors in endangered sea ... published Tuesday in the peer-reviewed open-access journal PeerJ ... in algae that the turtles eat, promoting the formation ... organs. , Scientists at Duke University, the University of ... conducted the study to better understand the causes ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Contaminated water linked to pregnancy complications, BU study finds 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... Autism Speaks applauds the consensus statement and recommendations ... disorders in children with autism spectrum disorders (ASD) released ... advancing physician awareness of unique challenges in the medical ... see the publication of these consensus recommendations. Autism Speaks, ...
... nerves are the likely origin of the Devil Facial Tumour ... an international team of scientists has discovered. Devil ... only Tasmanian devils and was first reported in 1996. It ... disease is characterised by large tumours, mostly on the face ...
... have new insight into the sex lives of the much-maligned ... deaths, according to a report published online on December 31st ... finding a partner of the right species type, male and ... harmony. Those tones are produced and varied based on the ...
Cached Biology News:Pediatrics GI recommendations -- first step to guidelines for children with autism 2Pediatrics GI recommendations -- first step to guidelines for children with autism 3Nervous culprit found for Tassie devil facial tumor disease 2To a mosquito, matchmaking means 'singing' in perfect harmony 2
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
X box-binding protein 1...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Biology Products: